On May 8, 2025, Benchmark analyst Robert Wasserman announced an update regarding Bio-Techne (TECH, Financial), a leading player in the biotechnology industry. Wasserman has decided to maintain the 'Buy' rating on the stock while lowering the price target from USD 95.00 to USD 75.00.
The adjustment in the price target represents a decrease of 21.05%. Despite the lowered price target, the 'Buy' recommendation indicates continued confidence in the stock's potential performance in the long term. The current price target for Bio-Techne (TECH, Financial) now stands at USD 75.00, reflecting Benchmark's revised outlook for the company's valuation.
Bio-Techne (TECH, Financial) continues to be a pivotal player in the market, with the latest analyst insights suggesting a favorable position for potential investors, despite the adjusted price projection.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Bio-Techne Corp (TECH, Financial) is $76.95 with a high estimate of $95.00 and a low estimate of $51.00. The average target implies an upside of 56.19% from the current price of $49.27. More detailed estimate data can be found on the Bio-Techne Corp (TECH) Forecast page.
Based on the consensus recommendation from 16 brokerage firms, Bio-Techne Corp's (TECH, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Bio-Techne Corp (TECH, Financial) in one year is $90.18, suggesting a upside of 83.05% from the current price of $49.265. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Bio-Techne Corp (TECH) Summary page.
